A Randomized Double Blind Comparison of Atosiban in Patients With RIF Undergoing IVF Treatment

• Status: Unknown status
• Trial end date: 2018-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

This study intends to carry out a prospective, randomized, double blind and controlled study to compare the influence of Atosiban and placebo on uterine contraction frequency, endometrial blood flow perfusion, oxytocin and serum concentration of PGF2α, embryo implantation rate and clinical pregnancy rate on the RIF population after fresh embryo transfer, so as to further clarify the curative effect of Atosiban in the treatment of RIF and provide evidence-based basis for Atosiban for application in RIF population.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai First Maternity and Infant Hospital
• Treatments: Atosiban; Oxytocin; Vasotocin

Criteria

Inclusion Criteria:

1. 3 or more than 3 embryo implantation failure histories previously (or the number of high-quality embryos transplanted is >4);

2. Age <40 years；

3. Ultrasound or HSG showed normal uterine cavity, endometrium on transplantation day is ≥ 8mm;

4. There's at least one good quality embryo on transplantation day.

Exclusion Criteria:

1. Patients using donor sperm or donor eggs;

2. Patients have obvious uterine cavity abnormalities;

3. There was a clear hydrosalpinx;

4. Natural cycles or IVM patients;

5. Patients who cancel the due to the transfer due to various reasons, such as the failure of fertilization, or ovarian transitional stimulus syndrome (OHSS);

6. Abnormal karyotype;

7. Blastocyst transplantation patients.